Combination therapy for osteoporosis: Considerations and controversy-Reference-Cited by-同舟云学术

Combination therapy for osteoporosis: Considerations and controversy

Published:2005-12 Issue:4 Volume:3 Page:150-154
ISSN:1544-1873
Container-title:Current Osteoporosis Reports
language:en
Short-container-title:Curr Osteoporos Rep

Author:

Binkley Neil,Krueger Diane

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s11914-996-0018-1.pdf

Reference38 articles.

1. Aloia JF, Zanzi I, Vaswani A, et al.: Combination therapy for osteoporosis. Metabolism 1977, 26:787–792.

2. Stepan JJ, Burckardt P, Hana V: The effects of three month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter’s syndrome: the influence of vitamin D deficiency and hormone status. Bone 2003, 33:589–596.

3. Krueger D, Nest L, Krause P, et al.: Vitamin D status, risedronate and bone turnover in nursing home residents. J Bone Miner Res 2004, 19(Suppl 1):S171.

4. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441.

5. Black DM, Cummings SR, Karpf DB, et al.: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535–1541.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methanolic extract of O.umbellata L. exhibits anti-osteoporotic effect via promoting osteoblast proliferation in MG-63 cells and inhibiting osteoclastogenesis in RANKL-stimulated RAW 264.7 cells;Journal of Ethnopharmacology;2023-10

2. Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials;Osteoporosis International;2018-12-11

3. Histological study of rat ovaries cryopreserved by vitrification or slow freezing and reimplanted in the early or late postmenopausal stage;Acta Cirurgica Brasileira;2014-05

4. Osteoclast differentiation inhibitors: a patent review (2008 – 2012);Expert Opinion on Therapeutic Patents;2013-10-04

5. Prevention of early bone loss around the prosthesis by administration of anti-osteoporotic agents and influences of collared and non-collared femoral stem prostheses on early periprosthetic bone loss;European Journal of Orthopaedic Surgery & Traumatology;2012-06-30